Cellebrite DI Ltd. has recently filed a Form 144, indicating its intention to sell shares as part of a stock transaction by an officer. This filing is significant as it demonstrates the company's ongoing management of stock compensation and reflects broader trends in the prepackaged software industry.
Background
Cellebrite DI Ltd. operates in the prepackaged software sector, classified under SIC code 7372. The company is listed on the Nasdaq under the ticker symbol CLBT. As a large accelerated filer, Cellebrite has been active in the market, with a series of filings that indicate ongoing transactions and corporate activities.
What the Filing Says
The Form 144, filed on November 10, 2026, details that David Gee, an officer of Cellebrite, intends to sell 653 ordinary shares. The shares are being sold as part of a mandatory, non-discretionary sell-to-cover arrangement to satisfy income tax liabilities incurred upon the vesting of restricted share unit awards. The filing states, "The reporting person intends to sell securities reported herein on 11/12/2026..."
Impact
This planned sale may affect shareholders and potential investors by providing insight into the company's stock management practices. It also highlights how executives handle their compensation through stock transactions, which can influence market perceptions of the company's financial health and governance.
What's Next
Following this filing, the approximate sale date for the shares is set for November 12, 2026. Further filings may provide additional context regarding the outcomes of these transactions.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










